FDA Approves Nerve Scaffold for the Treatment of Sensory Nerve Discontinuity
December 03, 2025
December 03, 2025
WASHINGTON, Dec. 3 -- The U.S. Department of Health and Human Services Food and Drug Administration issued the following news release:
* * *
FDA Approves Nerve Scaffold for the Treatment of Sensory Nerve Discontinuity
*
The U.S. Food and Drug Administration today granted approval for Avance (acellular nerve allograft-arwx) in surgical implantation. Avance is a peripheral nerve scaffold approved for sensory nerve discontinuities (<=25mm) (bre . . .
* * *
FDA Approves Nerve Scaffold for the Treatment of Sensory Nerve Discontinuity
*
The U.S. Food and Drug Administration today granted approval for Avance (acellular nerve allograft-arwx) in surgical implantation. Avance is a peripheral nerve scaffold approved for sensory nerve discontinuities (<=25mm) (bre . . .